Who
Reinaldo M. Diaz
Director
Company insider
Files Form 4 as: Director, Lexeo Therapeutics; Director, Inozyme Pharma; Director, Valentis.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 2 Dec 2005
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Jun 2024filed 27 Jun 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 10 Jun 2022filed 14 Jun 2022 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —9,367 at $0.00 | filing |
| 23 Jun 2021filed 24 Jun 2021 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —9,367 at $0.00 | filing |
| 23 Jul 2020filed 24 Jul 2020 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —9,367 at $0.00 | filing |
| 2 Dec 2005filed 9 Jan 2006 | Valentisoption or derivative | SEC FORM 4 Code A | —10,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.